Dr. Poma has served as MTEM’s Chief Executive Officer and Chief Scientific Officer since the Company’s inception in 2009. From March 2005 until September 2008, Dr. Poma was Vice President of Business Development of Innovive Pharmaceuticals (acquired by Cytrx Corporation), a biotechnology company. From 2001 to 2005, he served as the Associate Vice President of Business Development at ImClone Systems, Inc.(now Eli Lilly and Company) a biotechnology company focused on antibody therapeutics. As the founder and in his role as Chief Scientific Officer at MTEM, he led the invention of technology underlying MTEM’s platform technology and what constitutes the whole of MTEM’s current lead and preclinical pipeline candidates. Dr. Poma received his Ph.D. in Microbiology and Immunology and B.A. in Biology and from the University of North Carolina at Chapel Hill and his M.B.A. from New York University.
Mr. Kim serves as MTEM’s President, Chief Operating Officer, and Acting Chief Financial Officer. He served as MTEM’s Chief Financial Officer from February 2010 to August 2017. Previously, Mr. Kim led corporate development and strategic planning initiatives at OSI Pharmaceuticals (acquired by Astellas) and ImClone Systems (acquired by Lilly). He served as an investment professional at Domain Associates and Safeguard Scientifics where he focused on venture and public investments in biotechnology. Mr. Kim holds an MBA from The Wharton School and a BA in Neuroscience from Wesleyan University.
Dr. Ruskin joined MTEM in 2017 as SVP, General Counsel and Chief Patent Officer. Previously from 2015 to 2016, she served as SVP, General Counsel of Bionor Pharma and since May 2012 as President of BA Ruskin Law LLC where she advised biotechnology and pharmaceutical companies in worldwide patent portfolio management, litigation strategies, corporate transactions and due diligence. Prior to May 2012, Barbara was a partner at Ropes & Gray LLP in New York City and an associate at Fish & Neave LLP. She holds a J.D. from Fordham University School of Law (New York, NY), a Ph.D. in Biochemistry andMolecular Biology from Harvard University (Cambridge, MA) and a B.A. in Biochemistry from the University of California, Berkeley (Berkeley, CA). She is admitted to practice law in New York State and is a registered U.S. patent attorney.
Dr. Higgins joined Molecular Templates in 2010 and serves as the Company’s EVP of Operations and Head of Manufacturing. Previously, Dr. Higgins held leadership roles in the translation research group at the National Cancer Institute developing therapeutic cancer vaccines. Dr. Higgins holds a PhD and MS from the University of Arkansas where he focused on discovering and developing bio-therapeutics for the treatment of enteric disease.
Dr. Willert joined Molecular Templates in 2011 and serves as the Company’s Executive Vice President of R&D. Previously, Dr. Willert conducted research efforts focused on immune regulation of viral gene expression and biochemical characterization of therapeutic drug targets for parasitic disease. Dr. Willert completed her post-doctoral research at the Department of Pathology and Immunology at Washington University School of Medicine. Dr. Willert holds a PhD in Biochemistry from the University of Texas Southwestern Medical Center in Dallas.
Dr. Liu joined Molecular Templates in 2012 and serves as the Company’s Executive Vice President of Manufacturing. Previously, Dr. Liu served in various scientific and leadership roles at XBiotech and the Cancer Research Institute of Scott & White Healthcare. Dr. Liu holds a PhD in Biochemistry from the University of Rochester in New York.